The agenda is subject to change as priorities dictate.

In the event an individual cannot attend, written comments may be submitted. Any written comments received will be provided at the meeting and should be submitted to the contact person below well in advance of the meeting.

Contact Person for More Information: Theodore Katz, Executive Secretary, NIOSH, CDC, 1600 Clifton Road, Mailstop E–20, Atlanta, Georgia 30333, Telephone (513) 533–6800, Toll Free 1 (800) CDC–INFO, e-mail *ocas@cdc.gov*.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: January 7, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–524 Filed 1–12–09; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Child Care Quarterly Case Record Report—ACF–801.

OMB No.: 0970–0167.

Description: Section 658K of the Child Care and Development Block Grant Act of 1990 (Pub. L. 101–508, 42 U.S.C. 9858) requires that States and Territories submit monthly case-level data on the children and families receiving direct services under the Child Care and Development Fund. The implementing regulations for the statutorily required reporting are at 45 CFR 98.70. Case-level reports, submitted quarterly or monthly (at grantee option), include monthly sample or full population case-level data. The data elements to be included in these reports are represented in the ACF–801. ACF uses disaggregate data to determine program and participant characteristics as well as costs and levels of child care services provided. This provides ACF with the information necessary to make reports to Congress, address national child care needs, offer technical assistance to grantees, meet performance measures, and conduct research. Consistent with the statute and regulations, ACF requests extension of the ACF–801. With this extension, ACF is proposing several changes and clarifications to the reporting requirements and instructions.

Respondents: States, the District of Columbia, and Territories including Puerto Rico, Guam, the Virgin Islands, American Samoa, and the Northern Mariana Islands.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ACF–801	56	4	20	4,480

Estimated Total Annual Burden Hours: 4,480

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: *infocollection@acf.hhs.gov*.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Fax: 202–395–6974, Attn: Desk Officer for the Administration for Children and Families.

Dated: January 8, 2009.

Janean Chambers,

Reports Clearance Officer.

[FR Doc. E9–447 Filed 1–12–09; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2008–N–0038]

Advisory Committees; Tentative Schedule of Meetings for 2009

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2009. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. In its final report, one of the IOM's recommendations was for the agency to publish an annual tentative schedule of its meetings in the **Federal Register**. This publication implements the IOM's recommendation.

FOR FURTHER INFORMATION CONTACT: Theresa L. Green, Advisory Committee Oversight and Management Staff (HF–4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1220.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of the FDA's advisory committees. In its final report in 1992, one of the IOM's recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**; FDA has implemented this recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. Because the schedule is tentative, amendments to this notice will not be published in the **Federal Register**. However, changes to the schedule will be posted on the FDA

advisory committees' Internet site located at *http://www.fda.gov/oc/advisory/default.htm*. FDA will continue to publish a **Federal Register** notice 15 days in advance of each upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 2009. You may also obtain up-to-date information by calling the Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area).

Committee Name	Tentative Date of Meeting(s)	Advisory Committee 10-Digit Information Line Code
OFFICE OF THE COMMISSIONER		
Pediatric Advisory Committee	March 23–24, June 22–23, September 21–22, December 7–8	8732310001
Risk Communication Advisory Committee	February 26–27, April 30–May 1, August 13–14, November 12–13	8732112560
Science Board to the Food and Drug Administration	February 24, May 18, August 17, November 16	3014512603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH		
Allergenic Products Advisory Committee	March 5, October 22	3014512388
Blood Products Advisory Committee	January 9, April 1, July 20–21, November 16–17	3014519516
Cellular, Tissue and Gene Therapies Advisory Committee	May 14–15, November 5–6	3014512389
Transmissible Spongiform Encephalopathies Advisory Committee	To be announced	3014512392
Vaccines and Related Biological Products Advisory Committee	February 18–19, May 20–21, September 23–24, November 18–19	3014512391
CENTER FOR DRUG EVALUATION AND RESEARCH		
Anesthetic and Life Support Drugs Advisory Committee	January 29–30, April dates to be announced	3014512529
Anti-Infective Drugs Advisory Committee	To be announced	3014512530
Antiviral Drugs Advisory Committee	To be announced	3014512531
Arthritis Advisory Committee	March 5, June 16–17, October 27–28	3014512532
Cardiovascular and Renal Drugs Advisory Committee	February 3, March 18–19, July 28–29, December 7–8	3014512533
Dermatologic and Ophthalmic Drugs Advisory Committee	To be announced	3014512534
Drug Safety and Risk Management Advisory Committee	January 30, April dates to be announced	3014512535
Endocrinologic and Metabolic Drugs Advisory Committee	April 2–3	3014512536
Gastrointestinal Drugs Advisory Committee	February 17	3014512538
Nonprescription Drugs Advisory Committee	April dates to be announced	3014512541
Oncologic Drugs Advisory Committee	February 25, March 24–25, May dates to be announced, July 14–15, September 15–16, December 16–17	3014512542
Peripheral and Central Nervous System Drugs Advisory Committee	January 7–8	3014512543
Pharmaceutical Science and Clinical Pharmacology, Advisory Committee for	March dates to be announced	3014512539
Psychopharmacologic Drugs Advisory Committee	March 26	3014512544
Pulmonary-Allergy Drugs Advisory Committee	February 4	3014512545
Reproductive Health Drugs, Advisory Committee for	May and August dates to be announced	3014512537
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH		
Device Good Manufacturing Practice Advisory Committee	April 15, October 5–6	3014512398
Medical Devices Advisory Committee (Comprised of 18 Panels)		

Committee Name	Tentative Date of Meeting(s)	Advisory Committee 10-Digit Information Line Code
Anesthesiology and Respiratory Therapy Devices Panel	February 5, April 30, July 23, September 17, November 12	3014512624
Circulatory System Devices Panel	February 25, May 27, September 24	3014512625
Clinical Chemistry and Clinical Toxicology Devices Panel	March 18–19, June 17–18, October 21–22	3014512514
Dental Products Panel	February 11, May 6, June 17, September 16, December 9	3014512518
Ear, Nose, and Throat Devices Panel	February 24, May 19, August 18, November 17	3014512522
Gastroenterology-Urology Devices Panel	March 20, October 15	3014512523
General and Plastic Surgery Devices Panel	February 26–27, June 9–10, October 15–16	3014512519
General Hospital and Personal Use Devices Panel	March 25–26, July 29–30, October 21–22	3014512520
Hematology and Pathology Devices Panel	April 24, July 17, October 23	3014512515
Immunology Devices Panel	October 15–16	3014512516
Medical Devices Dispute Resolution Panel	Meetings occur as needed	3014510232
Microbiology Devices Panel	February 24–25, September 22–23, October 27–28	3014512517
Molecular and Clinical Genetics Panel	April 15, October 5–6	3014510231
Neurological Devices Panel	February 26–27, May 14–15, September 17–18, December 2–3	3014512513
Obstetrics and Gynecology Devices Panel	February 5–6, May 14–15, August 13–14, November 12–13	3014512524
Ophthalmic Devices Panel	February 12–13, May 14–15, September 24–25,November 19–20	3014512396
Orthopaedic and Rehabilitation Devices Panel	February 3–4, April 14–15, June 9–10, August 11–12, October 15–16, December 1–2	3014512521
Radiological Devices Panel	February 18, May 12, August 4, November 17	3014512526
National Mammography Quality Assurance Advisory Committee	November 4–5	3014512397
Technical Electronic Product Radiation Safety Standards Committee	No meeting tentatively scheduled for 2009	3014512399
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION		
Food Advisory Committee	May 20–21	3014510564
CENTER FOR VETERINARY MEDICINE		
Veterinary Medicine Advisory Committee	April 14	3014512548
NATIONAL CENTER FOR TOXILOGICAL RESEARCH (NCTR)		
Science Advisory Board to NCTR	November 17–18	3014512559

Dated: December 24, 2008.

Randall W. Lutter,

Deputy Commissioner for Policy.

[FR Doc. E9–451 Filed 1–12–09; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–D–0675]

Draft Guidance for Industry on Good Importer Practices; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing on behalf of several members of the Interagency Working Group on Import Safety (agencies) the availability of a draft guidance for industry entitled ''Good Importer Practices.'' This draft guidance document provides general recommendations to importers on possible practices and procedures they may follow to increase the likelihood the products they import are in